Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Endocrine Peptide Test Market Size Forecast: How Large Could The Market Become By 2030?

Significant expansion has characterized the market for endocrine peptide testing recently, with projections indicating continued robust growth. Estimates suggest the market will advance from a value of $9.95 billion in 2025 to $10.88 billion by 2026, demonstrating a compound annual growth rate of 9.3%. Historical expansion drivers for this sector have included a rise in endocrine disorder diagnoses, the increasing proliferation of diagnostic facilities, heightened public understanding of hormonal imbalances, innovations in immunoassay methodologies, and the broader development within the field of clinical endocrinology.

The market for endocrine peptide testing is projected to experience substantial expansion in the coming years, reaching an estimated $14.88 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.1% throughout the forecast period. This anticipated growth is powered by several key factors, including the increasing embrace of precision medicine, ongoing advancements in biomarker discovery, the growing adoption of automation within diagnostic laboratories, the emphasis on personalized endocrine care approaches, and a heightened demand for the early detection of medical conditions. Furthermore, significant trends shaping this market during the forecast interval encompass a rising need for diagnostics related to hormonal disorders, a greater utilization of peptide biomarkers in clinical settings, an expansion in the early identification of endocrine diseases, a broader scope for specialized laboratory testing services, and a concentrated effort on precise hormonal monitoring.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16675&type=smp

Endocrine Peptide Test Market Growth Factors Supporting Long-Term Expansion

The increasing incidence of diabetes is anticipated to be a significant catalyst for the expansion of the endocrine peptide test market in the future. Diabetes, characterized by elevated blood sugar (glucose) concentrations, is becoming more common due to a combination of factors including poor dietary habits, lack of physical activity, inherited genetic tendencies, and an increasingly elderly demographic. Endocrine peptide assays, such as those measuring hemoglobin A1c, fasting plasma glucose, and C-peptide, are essential for identifying diabetes, tracking blood sugar control, and evaluating how well the body produces and responds to insulin. Illustrating this trend, data from the UK’s National Health Service revealed a notable jump in diabetes diagnoses among individuals under 40, with numbers climbing from 173,166 in 2022 to 216,440 in 2023, a surge that highlights a worrying increase in diabetes among younger demographics and consequently fuels the demand for endocrine peptide testing.

Endocrine Peptide Test Market Segment Performance And Strategic Opportunities

The endocrine peptide test market covered in this report is segmented –

1) By Test-Type: Dehydroepiandrosterone Sulphate, Progesterone, Luteinizing Hormone, Thyroid Prolactin, Oestradiol, Human Chorionic Gonadotropin, Thyroid-Stimulating Hormone, Other Test-Types

2) By Technology: Mass Spectroscopy, Immunoassay, Chromatography, Nucleic Acid Based, Other Technologies

3) By End-User: Clinics, Healthcare Centers, Hospitals, Commercial Laboratories

Subsegments:

1) By Dehydroepiandrosterone Sulphate (DHEA-S): Immunoassay Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA)

2) By Progesterone: Immunoassay Tests, Chemiluminescence Assays, ELISA Tests

3) By Luteinizing Hormone: Immunoassay Tests, Enzyme Immunoassay (EIA), Radioimmunoassay (RIA)

4) By Thyroid Prolactin: Immunoassay Tests, Chemiluminescence Assays, Radioimmunoassay (RIA)

5) By Oestradiol: Immunoassay Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA)

6) By Human Chorionic Gonadotropin (hCG): Immunoassay Tests, Chemiluminescence Assays, Enzyme Immunoassay (EIA)

7) By Thyroid-Stimulating Hormone (TSH): Immunoassay Tests, Radioimmunoassay (RIA), Enzyme-Linked Immunosorbent Assay (ELISA)

8) By Other Test-Types: Cortisol, Insulin, Growth Hormone (GH), Parathyroid Hormone (PTH)

Endocrine Peptide Test Market Industry Trends Shaping Future Revenue Growth

Within the endocrine peptide testing sector, leading enterprises are focused on introducing immunoassay testing solutions to enhance the precision, responsiveness, and efficiency of endocrine peptide analysis, employing antibody-based techniques for the identification and quantification of particular peptides in biological samples like blood or urine, thereby equipping medical practitioners with crucial data concerning hormonal status and endocrine system performance, as exemplified by Siemens Healthineers’ introduction in July 2023 of the Atellica CI Analyzer, a streamlined platform for both immunoassay and clinical chemistry diagnostics, encompassing endocrine peptide evaluations, notably including a reproductive endocrinology suite featuring anti-Mullerian hormone (AMH) for assessing ovarian capacity and sFlt-1 and PlGF for predicting preeclampsia outcomes, all engineered for prompt, reliable outcomes at a throughput of up to 1000 tests per hour, thereby optimizing laboratory operations and adaptability to changing diagnostic demands.

Endocrine Peptide Test Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the endocrine peptide test market are Siemens AG, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Sciex, Bio-Techne Corporation, Invitae Corporation, ARUP Laboratories, Genova Diagnostics, Boston Heart Diagnostics Corporation, Immunodiagnostic Systems Ltd., Mayo Clinic Laboratories

Access The Complete Endocrine Peptide Test Market Report:

https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

Endocrine Peptide Test Market Regional Analysis: Which Region Leads By Revenue?

North Americawas the largest region in the endocrine peptide test market in 2025. The regions covered in the endocrine peptide test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model